Exhibit & Poster Presentations - Session III Viewing
9:00-10:00
Issues Panels – Session I (3 panels)
HEALTH POLICY
IP1: MEETING PROPOSED FDA STANDARDS FOR PATIENT REPORTED
OUTCOMES (PROS); ARE THEY ACHIEVABLE? Moderator: John Brodersen, MD, GP, PhD, University of
Copenhagen, Copenhagen, Denmark Panelist(s): Svend Kreiner, MSC, Associate Professor,
University of Copenhagen, Copenhagen, Denmark; Lynda Doward, MRes, Associate Director of Research, Galen
Research, Manchester, United Kingdom; Alan Tennant, BA,
PhD, Professor of Rehabilitation Studies, The University
of Leeds, Leeds, United Kingdom
USE OF HEALTH ECONOMIC/ PHARMACOECONOMIC INFORMATION BY
DECISION-MAKERS ISSUES
IP3: DO ECONOMISTS HAVE ANYTHING TO CONTRIBUTE TO HEALTH
ECONOMICS? Moderator: Joakim Ramsberg, PhD, Health economist,
Pharmaceutical Benefits Board, Solna, Sweden Panelist(s): Bengt Liljas, PhD, Value Demonstration
Leader, AstraZeneca, Mölndal, Sweden; F. Reed Johnson,
PhD, Senior Fellow and Principal Economist, Research
Triangle Institute, Research Triangle Park, NC, USA; Peter Zweifel, PhD, Professor, University of Zurich, Zurich,
Switzerland
IP7: EUROPEAN NETWORK FOR HEALTH TECHNOLOGY ASSESSMENT (EUnetHTA); MISSION AND EXPECTED OUTCOMES
Moderators: Finn Borlum Kristensen PhD,
Danish Centre for Evaluation and Health Technology
Assessment, Copenhagen, Denmark Panelists:Camilla Palmhøj Nielsen, Danish
Centre for Evaluation and Health Technology Assessment,
Copenhagen, Denmark; Debbie Chase, National Coordinating
Centre for Health Technology Assessment, Wessex
Institute for Health Research & Development, University
of Southampton, Southampton, UK; Kristian Lampe
or representative, Finnish Office for Health Technology
Assessment, Helsinki, Finland; Dr. Alric Rüther,
German Agency for Health Technology Assessment at the
German Institute for Medical Documentation and
Information, Cologne, Germany; Hans-Peter Dauben
MD, PhD, Head, International Affairs, German
Institute for Medical Documentation and Information,
Cologne, Germany, speaking for the National Authority of
Health, France.
10:00-10:30
Break, Exhibits, & Poster Presentation Viewing
- Session III
10:30-11:30
Issues Panels - Session II (3 panels)
HEALTH CARE REIMBURSEMENT / COVERAGE ISSUES
IP4: ARE INTERVENTIONS TO INFLUENCE UTILIZATION AND COSTS
OF PHARMACEUTICALS COST-EFFECTIVE? Moderator: Kjeld Møller Pedersen, PhD, Professor,
University of Southern Denmark, Odense, AL, Denmark Panelist(s): Ivar S Kristiansen, MD, PhD, MPH, Professor,
University of Oslo, Oslo, Norway; Douglas Lundin, PhD,
Health Economist, LFN Pharmaceutical Benefits Board, Solna,
Sweden; Eivind Jorgensen, MPhil, Health Economics Manager,
AstraZeneca Norway, Oslo, Norway
Lunch, Exhibits & Poster Presentations -
Session III
12:00-13:00
Author Presentation Hour
12:00-13:00
A Millcreek Outcomes Group and Novartis Symposium
THE IMPACT OF COMPLIANCE AND PERSISTENCE
ON THE ECONOMICS AND OUTCOMES OF HYPERTENSION
A Millcreek Outcomes Group and Novartis Symposium hosted
by the University of Utah Pharmacotherapy Outcomes
Research Center
Program Objectives of this symposium are: 1) To define
compliance and persistence in relation to the management
of hypertension; 2) To describe the outcomes of
non-compliance and non-persistence in hypertension; and
3) To list options to improve compliance and persistence
and overall patient outcomes in the management of
hypertension.
12:00–12:055
Introduction and Welcome Moderator: Diana Brixner PhD, Assoc. Professor and
Chair, University of Utah, Salt Lake City, UT, USA
12:05–12:20
Defining Compliance and Persistence in
Hypertension Speaker: Joyce Cramer BS, Associate Research
Scientist, Yale University,
New Haven, CT, USA
12:20–12:35
Economics and Outcomes of Non-Compliance and
Non-Persistence in Hypertension Speaker: Ron Herings PharmD, PhD, Pharmo Institute
for Drug Outcomes Studies, Utrecht, The Netherlands
12:30–12:40
Therapeutic Options to Maximize Antihypertensive
Compliance & Persistence Speaker: Kenneth Jackson PharmD, Assoc. Professor
(Clinical), University of Utah, Salt Lake City, UT,
USA
12:40–12:50
Q & A Panel Moderator: Diana Brixner PhD, Assoc. Professor and
Chair, University of Utah, Salt Lake City, UT, USA
12:50 – 13:00
Conclusion
13:00-14:20
SOCIETAL VALUE OF A QALY
Moderator: Ivar Sonbo Kristiansen MD, PhD, MPH,
University
of Oslo, Institute of Health Management and Health
Economics, Oslo, Norway
13:00-13:10
Introduction Speaker: Ivar Sonbo Kristiansen MD, PhD, MPH,
University of Oslo, Institute of Health Management and
Health Economics, Oslo, Norway
13:10-13:400
Looking for Willingness to Pay (WTP) Threshold for a
QALY-- Does it make sense? -- A Critical View Speaker: Dorte Gyrd-Hansen PhD, Professor,
University of Southern Denmark, Institute of Public
Health, Odense, Denmark
The main obstacles involved in establishing one unique
willingness to pay (WTP) estimate for the value of a
QALY are presented. WTP and QALY are two instruments
which can be applied to measure the effect of a health
care intervention, and in order to establish one WTP per
QALY threshold these scales must be linearly related.
Because CEA and CBA are two methods of economic
evaluation that are based on two very different
normative perceptions of the role of health versus other
goods in society, the task of performing a linear
translation form QALYs to WTPs is theoretically and
empirically unattainable.
13:40-14:10
Looking for Willingness to Pay (WTP) Threshold for a
QALY -- Does it make sense? -- A Practical View Speaker: Martin Buxton BA (Soc Sci), Professor,
Brunel University Health Economics Research Group,
Uxbridge, Middlesex, UK
Martin Buxton will argue that cost-effectiveness
analyses are only useful if they can be related to a
relevant cost-effectiveness threshold. In any health
care system with a predetermined budget, social WTP
values are interesting but irrelevant: the key factor is
the opportunity cost at the margin of the budget. The
WTP threshold needs to be set to ensure that
technologies adopted are always more valuable than other
new alternatives and any displaced activities. This
implies the need to identify and to cease using existing
technologies that are less cost-effective than new ones
that require funding.
14:10-14:20
Panel Discussion
14:20-14:30
Award Presentation
14:30-14:45
Break, Exhibits & Poster Presentations Viewing– Session III
14:45-15:45
Workshops Session III (7 workshops
)
ECONOMIC STUDY METHODS
W15: PRICE, AVAILABILITY AND AFFORDABILITY OF CHRONIC
DISEASE MEDICINES DISCUSSION LEADERS: Richard Laing, MBCHB, MSc, MD, Medical
Officer, WHO, Geneva, Switzerland; Margaret Ewen, Dip,
Pharm, Principal, Global Projects, Health Action
International Europe, Amsterdam, The Netherlands; Susanne FAM. Gelders, MSc, Technical Officer, World Health
Organization, Geneva, Switzerland
W16: SHOULD THE LOWER COST OF GENERICS OR PARALLEL IMPORTS
BE APPLIED TO ECONOMIC EVALUATIONS? DISCUSSION LEADERS: Donald Macarthur, BSc, Senior
Consultant, PriceSpective Limited, Buntingford,
Hertfordshire, United Kingdom; Keiron Sparrowhawk, MSc,
MBA, Principal, PriceSpective Limited, Buntingford,
Hertfordshire, United Kingdom; Stephen Beard, MSc, Head of
Health Economics, RTI Health Solutions, Manchester,
Greater Manchester, United Kingdom
HEALTH CARE POLICY
W17: THE IMPLICATIONS OF REQUIREMENTS FOR SUBPOPULATION
ANALYSES: THE DUTCH EXPERIENCE DISCUSSION LEADERS: Mark JC Nuijten, MD, PhD, MBA,
Consultant, Ars Accessus Medica/Erasmus University
Rotterdam, Amsterdam, The Netherlands; Carin Uyl-de Groot,
PhD, Professor, IMTA, Rotterdam, The Netherlands; Frans
Rutten, PhD, Professor, IMTA, Rotterdam, The Netherlands
W23: STRUCTURAL SENSITIVITY ANALYSIS WITH DES DISCUSSION LEADERS: Jorgen Moller, MSc, Arena Specialist, Caro Research Institute, Concord, MA, USA;
H. Baris Deniz,
MSc, Researcher, Caro Research Institute, Concord, MA,
USA; J. Jaime Caro, MDCM, FRCPC, FAC, President &
Scientific Director, Caro Research Institute, Concord, MA,
USA
W26: NUMBER NEEDED TO TREAT: MISLEADING, MISUNDERSTOOD,
MISUSED? DISCUSSION LEADERS: Jørgen Nexøe, PhD, General
Practitioner, Senior Researcher, University of Southern
Denmark, Odense, Denmark; Peder Halvorsen, PhD-student,
General Practitioner, University of Southern Denmark,
Odense, Denmark; Palle Mark Christensen, PhD, Clinical
Pharmacologist, University of Southern Denmark, Odense,
Denmark; Ivar S Kristiansen, MD, PhD, MPH, Professor,
University of Oslo, Oslo, Norway
W28: USING REAL WORLD DATA TO FOLLOW UP REIMBURSEMENT
DECISIONS Discussion Leaders: Andreas Engstrom, MSc, Health
Economist, LFN Pharmaceutical Benefits Board, Solna,
Sweden; Gepke Delwel, PhD, Policy Advisor, CVZ Health care
Insurance Board, Diemen, The Netherlands; Johan Brun, MD,
Medical Director, Pfizer AB, Sollentuna, Sweden
